Cargando…
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
Poly-(ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) are key enzymes in the DNA damage response. Four different inhibitors (PARPi) are currently in the clinic for treatment of ovarian and breast cancer. Recently, histone PARylation Factor 1 (HPF1) has been shown to play an essential role in the PA...
Autores principales: | Rudolph, Johannes, Roberts, Genevieve, Luger, Karolin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854685/ https://www.ncbi.nlm.nih.gov/pubmed/33531508 http://dx.doi.org/10.1038/s41467-021-20998-8 |
Ejemplares similares
-
HPF1 and nucleosomes mediate a dramatic switch in activity of PARP1 from polymerase to hydrolase
por: Rudolph, Johannes, et al.
Publicado: (2021) -
SPINDOC binds PARP1 to facilitate PARylation
por: Yang, Fen, et al.
Publicado: (2021) -
PARP1 mediated PARylation contributes to myogenic progression and glucocorticoid transcriptional response
por: Tan, Arnold, et al.
Publicado: (2023) -
Slow Dissociation
from the PARP1–HPF1 Complex
Drives Inhibitor Potency
por: Stojanovic, Petra, et al.
Publicado: (2023) -
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
por: Min, Ahrum, et al.
Publicado: (2020)